The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,811.00
Ask: 1,811.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 1,805.00
High: 1,812.50
Low: 1,797.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Ignoring WHO call, major nations stick to vaccine booster plans

Thu, 05th Aug 2021 09:09

* Global body disapproves of boosters until more people
vaccinated

* Some rich nations going ahead anyway to fend off Delta
variant

* Elderly and vulnerable to benefit first from booster shots

* Low-income nations suffer from lack of vaccine supplies
(Adds details throughout)

By Sudip Kar-Gupta and Caroline Copley

PARIS/BERLIN, Aug 5 (Reuters) - Germany, France and Israel
will go ahead with plans to administer COVID-19 vaccine
boosters, disregarding an appeal by the World Health
Organisation to hold off until more people are vaccinated around
the world.

The decision to press ahead with booster shots despite the
WHO's strongest statement yet highlights the huge inequities in
responses to the pandemic as richer nations ramp up programmes
to protect citizens from the more infectious Delta variant.

French President Emmanuel Macron said France was working on
rolling out third doses to the elderly and vulnerable from
September.

Germany intends to give boosters to immunocompromised
patients, the very elderly and nursing home residents from
September, the health ministry said.

Israeli Prime Minister Naftali Bennett urged older citizens
to get a third shot after the government last month kicked off a
campaign to give booster doses.

"Whoever is over the age of 60, and has yet to receive the
third dose of the vaccine, is six times more susceptible to
severe illness and - heaven forbid - death," Bennett said in a
statement.

WHO chief Tedros Adhanom Ghebreyesus called on Wednesday for
a halt to boosters until at least the end of September, saying
it was unacceptable for rich countries to use more of the global
vaccine supply.

INEQUALITIES MOUNT

High-income countries administered around 50 doses for every
100 people in May, and that number has since doubled, according
to WHO. Low-income countries have only been able to administer
1.5 doses for every 100 people, due to lack of supplies.

"I understand the concern of all governments to protect
their people from the Delta variant. But we cannot accept
countries that have already used most of the global supply of
vaccines using even more of it," Tedros said.

Germany rejected those accusations, saying it would also
donate at least 30 million vaccine doses to poorer countries.

"We want to provide the vulnerable groups in Germany with a
precautionary third vaccination and at the same time support the
vaccination of as many people in the world as possible," the
health ministry said.

Following Tedros' comments, the White House said on
Wednesday it was prepared to provide booster shots if needed,
suggesting it would not heed the WHO's call either.

Pfizer has said boosters are most likely needed
because of waning antibody responses, particularly after six
months.

U.S. health regulators have said that more scientific
evidence is needed to be certain boosters are needed, but have
indicated they believe a third shot may be needed for people
with compromised immune systems.

Macron's government is trying to step up France's
vaccination programme as the country faces a fourth wave of the
virus and street demonstrations in protest against the
government's COVID policies.

France and Germany have so far given at least one dose of a
COVID-19 vaccine to 64.5% and 62% of their respective
populations, with 49% of the French and 53% of Germans fully
vaccinated.

(Reporting by Sudip Kar-Gupta and Nicolas Delame in Paris,
Alexander Ratz and Caroline Copley in Berlin; Editing by Nick
Macfie, Josephine Mason, Andrew Cawthorne)

More News
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.